In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Organon & Co. stands eleventh among them.
Organon & Co., a global healthcare company focused on women’s health, biosimilars, and established pharmaceuticals, has been steadily expanding its footprint since spinning off from Merck in 2021. The company has strategically targeted biosimilars and critical therapies for underserved populations, positioning itself for growth in specialty and high-value treatments.
This month, Organon & Co. scored a major milestone with FDA approval of BILDYOS and BILPREVDA, biosimilars to PROLIA and XGEVA, respectively. Developed in partnership with Shanghai Henlius Biotech, these approvals mark a significant step in improving access to osteoporosis and bone cancer treatments. By providing cost-effective alternatives without compromising efficacy, the business aims to address the needs of aging populations and patients requiring critical bone care.
The corporation’s broader strategy reflects a pivot toward biosimilars as a growth engine while maintaining its core focus on women’s health and dermatology products. Organon & Co. is also expanding into oncology and immunology, building a pipeline designed to balance challenges from legacy brands with aggressive entries into high-value generics and specialty therapies.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure. None.
